The phase III KEYNOTE-604 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival in the first-line treatment of patients with extensive stage small cell lung cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe